Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med
05:20am, Thursday, 18'th Feb 2021
Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to pu
Y-mAbs Announces Pricing of Public Offering of Common Stock
07:14pm, Wednesday, 17'th Feb 2021
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
Y-mAbs Announces Sale of Priority Review Voucher
09:00am, Monday, 28'th Dec 2020
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Therapeutics: Further Upside After Approval
10:01pm, Monday, 21'st Dec 2020
Y-mAbs Therapeutics recently had its first approval. Its second drug, despite some hiccups, is on its way to the market.
Week In Review: Week's China Life Science Investments Total $800 Million
03:01pm, Sunday, 20'th Dec 2020
Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing a
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
09:05am, Friday, 18'th Dec 2020
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
09:00am, Friday, 18'th Dec 2020
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
09:00am, Friday, 04'th Dec 2020
NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused o
FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
05:02pm, Wednesday, 25'th Nov 2020
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Announces Update on Omburtamab in DIPG
09:00am, Thursday, 19'th Nov 2020
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript
07:31am, Sunday, 08'th Nov 2020
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript
Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications
09:10am, Monday, 26'th Oct 2020
NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and
